Online ISSN: 2515-8260

Author : Abilkosimovna, Kardjavova Gulnoza

Evaluation Of The Effectiveness Of Montelukast In Children With Recurrent Obstructive Bronchitis

Lim Maksim Vyacheslavovich; Shavazi Nurali Muhammad ugli; Kardjavova Gulnoza Abilkosimovna; Gaybullaev Javlon Shavkatovich; Allanazarov Alisher Boymuradovich

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 3, Pages 2507-2515

Background: The objective of the study was to evaluate the effectiveness of montelukast sodium in the treatment and prevention of recurrent obstructive bronchitis in children.
Methods: 80 children aged 1 to 7 years with recurrent obstructive bronchitis were enrolled and randomly divided into 2 groups. Group I (control) included 40 patients who received standard therapy. Group II (main) included 40 patients who received oral montelukast sodium. The effectiveness of the therapy was evaluated by cough relief, sputum separation, RDAI scale, and modified bronchophonography indicator.
Results: Patients who received montelukast had significantly accelerated elimination of cyanosis (by 0.7 days; P<0.05), cough relief (by 0.9 days; P<0.05), disappearance of respiratory failure (by 0.7 days; P<0.05) in comparison with the control group. Positive dynamics of indicator E:I index was observed on average starting from 3 days (P<0.05) until the last day of inpatient treatment (P<0.01) in patients of the main group in comparison with the control group. The anti-relapse effect of montelukast sodium, detected during follow-up of patients for 12 months after discharge, was established, so the frequency of repeated episodes of the disease was 33-59% less frequent in patients of the main group (P<0.01; P<0.001).
Conclusion: Using of montelukast sodium in recurrent obstructive bronchitis in children contributes to significant progress in the dynamics of the disease, leads to a significant decrease in the severity of bronchial obstruction according to the E: I index. The use of the drug causes a decrease in repeated relapses of the disease within 12 months.